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in the control littermates. Interestingly, the authors also found 
that lipocalin 2 increased upon epidermal growth factor receptor 
(EGFR) activation, and that EGFR inhibition prevented lipocalin 
2 upregulation and development of renal lesions.
Thus, lipocalin 2 is a target of EGFR signaling, mediates its pro-
liferative action, and acts as a growth regulator. Probably for this 
reason, it appears to have an important role in the progression of 
chronic kidney diseases.
Juan Oliver
In-center hemodialysis  
six times per week versus  
three times per week
Frequent Hemodialysis Network Trial Group, N Engl J Med advance online 
publication, 20 November 2010, doi:10.1056/NEJMoa1001593
The Frequent Hemodialysis Network completed two trials com-
paring in-center six-times-weekly and nocturnal six-times-
weekly dialysis with conventional in-center three-times-weekly 
hemodialysis. Both trials were presented at the Late-Breaking 
Trials session of the American Society of Nephrology meeting 
on 20 November 2010, and the results from the trial of in-center 
daily (six times per week) dialysis were published in the New 
England Journal of Medicine. In this trial, 245 patients were ran-
domized to receive daily dialysis (six times per week) or con-
ventional three-times-weekly dialysis. The primary end points 
were composites of one-year mortality and either a change in left 
ventricular mass index (LVMI) or a change in the 36-Item Short 
Form Health Survey (SF-36) score among survivors at one year. 
For the purposes of calculating changes in LVMI and SF-36 score, 
patients who died were assigned the worst potential outcomes. 
The group randomized to three-times-weekly dialysis received a 
dialysis dose of 1.1 equilibrated Kt/V. The goal dialysis dose for 
patients randomized to daily dialysis was 0.9 equilibrated Kt/V. 
The average age of participants was 50.4 years, and 45% had a 
dialysis vintage greater than 5 years. Thirty-eight percent of par-
ticipants were women, 42% were black, and 41% had diabetes 
mellitus. The group randomized to conventional dialysis received 
an average of 2.88 dialysis treatments per week, while the group 
randomized to daily dialysis received 5.17 dialysis treatments per 
week, providing a 40% greater delivered dose of dialysis in the 
daily-dialysis group. Participants receiving daily dialysis had a 
lower risk of death or an increase in left ventricular mass (hazard 
ratio (HR), 0.61; 95% confidence interval (CI), 0.46–0.82) and 
of death or a decrease in SF-36 physical-health composite score 
(HR, 0.70; 95% CI, 0.53–0.92). No difference in treatment effect 
was seen among clinical subgroups based on age, sex, and other 
clinical characteristics. No differences were seen between arms in 
the secondary outcomes of depression, albumin measurements, 
and erythropoiesis-stimulating agent dose. However, improved 
control of hypertension and hyperphosphatemia was seen in 
participants receiving daily dialysis. With respect to safety, the 
Unexpected role of lipocalin 2  
in kidney disease progression
Viau et al., J Clin Invest 2010; 120: 4065–4076; doi:10.1172/JCI42004
Among the most common and poorly understood characteristics 
of many diseases of the kidney is their inexorable progression to 
end-stage renal function. A major breakthrough in the field was 
the finding that, absent direct kidney injury, reduction of the nor-
mal renal mass could also trigger progression to end stage. Experi-
ments in different mouse strains quickly revealed that the response 
to nephron reduction was greatly modified by genetic factors. For 
example, while 5/6 nephrectomy induced marked renal sclerosis 
in Swiss Webster and 129/Sv mice, C57BL/6 mice were found to be 
notoriously resistant to this insult. Similarly, nephron reduction in 
FVB/N mice induced severe renal lesions, but B6D2F1 mice (F1 of 
C57BL/6 × DBA2) only developed tubular and glomerular hyper-
trophy without glomerular sclerosis, tubular dilations, or inter-
stitial fibrosis. Viau et al. have now used these two mouse strains 
and performed gene expression analysis in their respective kidneys 
after nephron reduction. Two months after 75% nephrectomy, they 
identified 70 genes whose expression level differed significantly, 
with the Lcn2 gene (which codes for lipocalin 2, also known as 
neutrophil gelatinase-associated lipocalin (NGAL)) being the max-
imally upregulated one in the kidney of the disease-prone FVB/N 
strain. In situ hybridization and immunohistochemistry showed 
a marked and selective increase in Lcn2 mRNA and protein in 
the damaged kidneys of FVB/N mice (Figure). To determine the 
potential role of lipocalin 2 in renal disease progression, they exam-
ined the response to 75% renal reduction in mice with lipocalin 2 
gene deletion (Lcn2–/–) and found that the frequency and severity 
of the renal lesions were markedly reduced. Similarly, renal func-
tion was better preserved in the lipocalin 2-deficient mice than 
Lcn2 is overexpressed after nephron reduction in FVB/N mice.  
In situ hybridization (left) and immunohistochemistry (right) of 
Lcn2 expression in kidneys from sham-operated (control) and 75% 
nephrectomized (Nx) mice.
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time to first vascular-access intervention was shorter for partici-
pants receiving daily dialysis (HR, 1.71; 95% CI, 1.08–2.73), but 
no difference in vascular-access failure rate was seen (19 in the 
daily group versus 23 in the conventional group).
These favorable results support the use of daily dialysis, given the 
demonstrated benefit in all-cause mortality, physical functioning, 
and LVMI.
Lynda Szczech
Insulin signaling to the glomerular 
podocyte is critical for normal 
kidney function
Welsh et al., Cell Metab 2010; 12: 329–340; doi:10.1016/j.cmet.2010.08.015
Diabetic nephropathy (DN) is the leading cause of renal failure in 
the world. Besides causing a generalized microvascular disease, 
DN also causes changes in podocytes and results in podocyte 
loss, which has been related to the development of proteinuria 
and glomerulosclerosis. In previous publications, Welsh and col-
leagues showed that, within the glomerulus, podocytes are also 
uniquely insulin-sensitive in terms of glucose transporter-regu-
lated glucose uptake.1,2 Now they have shown that insulin sensitiv-
ity is crucial for maintaining the glomerular filtration barrier, by 
generating mice with podocyte-restricted deletion of the insulin 
receptor. These animals develop significant albuminuria together 
with histological features that recapitulate DN, but in a normogly-
cemic environment. Examination of ‘normal’ insulin-responsive 
podocytes in vivo and in vitro demonstrates that insulin signals 
through the MAPK and PI3K pathways via the insulin receptor 
and directly remodels the actin cytoskeleton of this cell.
The authors postulate that insulin resistance of podocytes in 
diabetes mellitus may play an important and novel role in the 
development of DN. However, it remains to be seen whether 
podocytes, or other renal cells, are insulin-resistant in diabetes and 
metabolic syndrome in other animal models and in humans.
Detlef Schlöndorff
1Diabetes 2005; 54: 3095–3102. 2Diabetes 2007; 56: 1127–1135.
Transgenic overexpression  
of CD39 protects against renal 
ischemia–reperfusion and 
transplant vascular injury
Crikis et al., Am J Transplant 2010; 10: 2586–2595; doi:10.1111/j.1600-
6143.2010.03257.x
The success of transplantation is dependent on the 
state of the donor organ, which is directly impacted by 
ischemia–reperfusion injury (IRI). IRI occurs at the time of 
organ retrieval, storage, and engraftment, and outcomes vary 
as to the extent of both warm and cold ischemia. The vascu-
lar ectonucleotidases CD39 (ectonucleoside triphosphate 
diphosphohydrolase-1) and CD73 generate adenosine from 
extracellular nucleotides. CD39 activity is critical in determin-
ing the response to IRI, and CD39-null mice exhibit heightened 
sensitivity to renal IRI. Adenosine has multiple mechanisms 
of action in the vasculature, including direct endothelial pro-
tection and anti-inflammatory and antithrombotic effects, 
and is protective in several models of IRI. Mice transgenic for 
human CD39 (hCD39) have an increased capacity to generate 
adenosine. Crikis et al. hypothesized that hCD39 transgenic 
mice would be protected from renal IRI. The overexpression 
of hCD39 conferred protection in a model of warm renal IRI, 
with reduced histological injury, less apoptosis, and preserved 
serum creatinine and urea levels. Benefit was abrogated by pre-
treatment with an adenosine A2A receptor antagonist. Adop-
tive transfer experiments showed that expression of hCD39 
on either the vasculature or circulating cells mitigated IRI. 
Furthermore, hCD39 transgenic kidneys transplanted into 
syngeneic recipients after prolonged cold storage performed 
significantly better and exhibited less histological injury than 
wild-type control grafts. Increasing experimental evidence sup-
ports a role for early nonspecific inflammatory events occurring 
in the peritransplant period, such as IRI, in the pathogenesis 
of delayed graft function, acute rejection, and chronic allograft 
dysfunction. The transgenic expression of hCD39 mitigates 
tubular-cell apoptosis and necrosis, which are features of IRI, 
in part by the generation of adenosine (Figure).
The delivery of CD39 in the clinic may be achieved with 
modification of soluble CD39 such that it is targeted to sites 
of endothelial injury, thereby providing putative anticoagulant 
and anti-inflammatory effects that are localized to the graft with 
minimal systemic effect.
Marc De Broe
hCD39 transgenic mice are protected from renal IRI. Abbreviations: H&E, 
hematoxylin and eosin; NS, not significant; PAS, periodic acid–Schiff; TG, 
transgenic; WT, wild type.
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